MYND Life Sciences Inc.

OTC: MYNDF · Healthcare · Biotechnology

Canadian filerHQ Kelowna, BCReports USD

#1052 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 23

v0.1 · 5/100 weight · pillars only

↑ Piotroski F, market scale · ↓ balance-sheet leverage, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$1.1M

Employees

—

Market cap

$657.8k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$68.9k93.0k CAD2023

Net income-$1.1M-1.5M CAD2023

Operating income-$1.4M-1.8M CAD2023

Total assets$575.0k797.5k CAD2023

Liabilities$4.2M5.8M CAD2023

Equity-$3.6M-5.0M CAD2023

Revenue trend

FY2019 – FY2023 · USD

FY19

FY20

FY21

FY22

$68.9k

FY23

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

MYND Life Sciences Inc. booked $68.9k in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -1632.3% net margin.

Peers · Healthcare

Clearside Biomedical, Inc.——Medical Care Technologies Inc.——Cannabis Suisse Corp.38D Windtree Therapeutics, Inc.——

Key facts

CEOWilfred A. Jefferies

SectorHealthcare

IndustryBiotechnology

HeadquartersKelowna, BC

ExchangeOTC: MYNDF

Employees—

IPO date2021-09-22

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.